Status: Recruiting
Evaluation of Non-Invasive Tests for Metabolic Liver Disease
The Non-Invasive Biomarkers for Metabolic Liver Disease (NIMBLE) study is a comprehensive, multi-year collaborative effort to standardize, validate and advance the regulatory qualification of blood- and imaging-based biomarkers to diagnose and stage Metabolic dysfunction-associated steatohepatitis (MASH), previously known as nonalcoholic steatohepatitis (NASH). MASH is characterized by liver inflammation accompanied by simultaneous fat accumulation in the liver.
Participants needed: 400
Trial details
Age: 18-75Biological sex: AllType: ObservationalSponsor: Foundation for the National Institutes of HealthUpdated: Aug 14, 2025Locations: 4
Eligibility criteria
Provision of signed and dated informed consent form [+2]
Known history or evidence of other forms of chronic liver disease other than MAS... [+20]